“Qu creates an environment where people and ideas connect to drive true innovation.”
Leading edge research
Qu Biologics recognizes the substantial benefit gained from synergistic research collaborations with industry and academia. Collaborations provide access to technological advances and new scientific breakthroughs, leading to faster progress towards the goal of finding safe and effective treatments and cures.
Qu Biologics has teamed up with a number of universities to collaborate on research projects. Collaborations include:
University of British Columbia, Dr. Bruce Vallance – Dr. Vallance’s team is studying the therapeutic effects of Qu Biologics’ SSI treatment for inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in a mouse model that mimics the underlying innate immune system defect and chronic bacterial infection associated with these diseases.
Geisel School of Medicine, Dartmouth College, Dr. David Mullins – Qu’s collaboration with Dartmouth College researches tumour targeting and the range of mechanisms by which Qu Biologics’ Site Specific Immunomodulator (SSI) therapy leads to the killing of cancer cells. These studies are conducted at the laboratory of Dr. David Mullins at the Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire.
University of Rochester School of Medicine’s Dr. Michael Elliott – Qu is collaborating with Dr. Michael R. (Rusty) Elliott, Assistant Professor of Microbiology at the University of Rochester School of Medicine. Dr. Elliott is a recognized expert in macrophage function and cell clearance, and his lab is testing the capacity of SSIs to activate macrophages for enhanced activity in vivo using novel preclinical mouse models and state-of-the-art immunologic assays systems.
McMaster University’s Dr. Dawn Bowdish – This collaboration researches the effect of SSI therapy on macrophage immune dysfunction. The studies are designed to assess the capacity of lung-targeted SSI therapy to restore normal lung and bone marrow macrophage function, and to assess macrophage function in response to SSI therapy in a variety of in vivo and in vitro assays. Additional studies, currently underway, are designed to assess efficacy in additional disease indications. The study is being carried out at McMaster University under the guidance of Dr. Dawn Bowdish, an expert in macrophage dysfunction. Dr. Dawn Bowdish is an Assistant Professor of Pathology and Molecular Medicine at the McMaster Immunology Research Centre.
McMaster University’s Dr. Brian Coombes – This collaboration studied Qu Biologics’ SSIs in a novel model animal model of inflammatory bowel disease, associated with chronic adherent invasive E. coli infection. McMaster University Associate Professor and Canada Research Chair, Dr. Brian Coombes, a microbiology expert, oversaw the study. Dr. Coombes’ recently published work in Nature Communications demonstrated that infection of mice with a strain of Crohn’s associated adherent-invasive E. coli leads to the development of intestinal inflammation in the mice which closely resembles human Crohn’s disease. His research model allows the study of Crohn’s disease in a chronic state.